{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:30:17Z","timestamp":1769203817319,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,8]]},"DOI":"10.7759\/cureus.12582","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T17:54:45Z","timestamp":1610128485000},"source":"Crossref","is-referenced-by-count":3,"title":["Vedolizumab (Entyvio\u00ae) for the Treatment of Pyoderma Gangrenosum in a Crohn\u2019s Disease Patient"],"prefix":"10.7759","author":[{"given":"Kevin","family":"Groudan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Singhania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence","volume":"21","author":"Scribano ML","year":"2018","unstructured":"Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018, 21:2457-2467. 10.3748\/wjg.v24.i23.2457","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan BG","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al.. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013, 369:699-710. 10.1056\/NEJMoa1215734","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn WJ","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al.. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013, 369:711-721. 10.1056\/NEJMoa1215739","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher M","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, et al.. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018, 63:825-833. 10.1007\/s10620-018-4971-1","journal-title":"Dig Dis Sci"},{"key":"ref5","article-title":"Pyoderma gangrenosum","author":"Schmieder SJ","year":"2020","unstructured":"Schmieder SJ, Krishnamurthy K. Pyoderma gangrenosum. StatPearls, Treasure Island (FL); 2020."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-19","article-title":"Pyoderma gangrenosum - a review","volume":"15","author":"Wollina U","year":"2007","unstructured":"Wollina U. Pyoderma gangrenosum - a review. Orphanet J Rare Dis. 2007, 15:19. 10.1186\/1750-1172-2-19","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka SR","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, et al.. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015, 21:1982-1992. 10.1097\/MIB.0000000000000392","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord M","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, et al.. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016, 10:239-254. 10.1093\/ecco-jcc\/jjv213","journal-title":"J Crohns Colitis"},{"key":"ref9","article-title":"Resolution of pyoderma gangrenosum with vedolizumab in a Crohn\u2019s patient","volume":"112","author":"Koduru P","year":"2017","unstructured":"Koduru P, Irani M, Abraham B. Resolution of pyoderma gangrenosum with vedolizumab in a Crohn\u2019s patient. Am J Gastroenterol. 2017, 112:1091.","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher M","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, et al.. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018, 63:825-833. 10.1007\/s10620-018-4971-1","journal-title":"Dig Dis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.01.012","article-title":"Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab","volume":"3","author":"Yeh JE","year":"2017","unstructured":"Yeh JE, Tsiaras WG. Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab. JAAD Case Rep. 2017, 3:110-112. 10.1016\/j.jdcr.2017.01.012","journal-title":"JAAD Case Rep"},{"key":"ref12","article-title":"Vedolizumab-induced pyoderma gangrenosum in a patient with ulcerative colitis","volume":"112","author":"Kim SB","year":"2017","unstructured":"Kim SB, Liege D, Maria A. Vedolizumab-induced pyoderma gangrenosum in a patient with ulcerative colitis. Am J Gastroenterol. 2017, 112:1106-1107.","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48844-vedolizumab-entyvio-for-the-treatment-of-pyoderma-gangrenosum-in-a-crohns-disease-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:26Z","timestamp":1707507146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48844-vedolizumab-entyvio-for-the-treatment-of-pyoderma-gangrenosum-in-a-crohns-disease-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.12582","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}